Profile data is unavailable for this security.
About the company
Theracryf PLC, formerly Evgen Pharma plc, is a clinical-stage therapeutics company. The Company is engaged in developing a new generation of therapeutics in oncology and behavioral brain disorders. Its pipeline and lead compound SFX-01 is derived from its proprietary Sulforadex technology. Its Sulforadex technology synthesizes sulforaphane into an active, stable, and solid form pharmaceutical ingredient, unlocking its medical and commercial potential. SFX-01 is a complex of sulforaphane and alpha-cyclodextrin formulated as a stable tablet. The Company has a candidate orexin 1 antagonist at late preclinical stage targeting addictive behaviors. It also has a candidate molecule DAT inhibitor at late preclinical stage targeting fatigue and narcolepsy.
- Revenue in GBP (TTM)396.00k
- Net income in GBP-3.14m
- Incorporated2014
- Employees9.00
- LocationTheraCryf PLCSuite 24G13 - Block 24 Alderley ParkCongleton Road, Nether AlderleyNETHERTON SK10 4TGUnited KingdomGBR
- Phone+44 162 531 5090
- Websitehttps://evgen.com/
Mergers & acquisitions
Acquired company | TCF:LSE since announced | Transaction value |
---|---|---|
Chronos Therapeutics Ltd | -13.16% | 4.33m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ovoca Bio PLC | 0.00 | -4.30m | 1.11m | 5.00 | -- | 0.5251 | -- | -- | -0.0527 | -0.0485 | 0.00 | 0.0238 | 0.00 | -- | -- | 0.00 | -79.30 | -25.19 | -94.61 | -27.65 | -- | -- | -- | -- | 6.55 | -1,019.80 | 0.00 | -- | -- | -- | 9.05 | -- | -- | -- |
ReNeuron Group Plc | 249.00k | -5.07m | 1.93m | 34.00 | -- | 0.7966 | -- | 7.75 | -0.0888 | -0.0888 | 0.0044 | 0.0424 | 0.0246 | -- | 0.6442 | 7,323.53 | -50.10 | -43.12 | -101.09 | -58.50 | -- | -- | -2,037.35 | -714.73 | -- | -- | 0.1247 | -- | 31.51 | 65.26 | 44.18 | -- | -1.31 | -- |
Fusion Antibodies PLC | 1.58m | -2.84m | 2.96m | 50.00 | -- | 1.27 | -- | 1.87 | -0.0861 | -0.0861 | 0.0436 | 0.0245 | 0.5229 | 3.15 | 1.88 | 31,580.00 | -93.94 | -31.29 | -130.56 | -37.72 | -7.41 | 42.58 | -179.67 | -48.25 | 2.32 | -- | 0.0313 | -- | -39.55 | 1.52 | -116.33 | -- | -23.83 | -- |
ValiRx Plc | 9.60k | -2.04m | 3.31m | 8.00 | -- | 0.7948 | -- | 344.66 | -0.0201 | -0.0201 | 0.00009 | 0.0315 | 0.0027 | -- | 0.0682 | -- | -59.88 | -50.57 | -58.27 | -54.77 | 85.00 | -- | -22,164.48 | -103,908.50 | 2.32 | -520.03 | 0.0075 | -- | -- | -- | 13.89 | -- | -1.13 | -- |
IXICO PLC | 6.00m | -1.87m | 3.38m | 89.00 | -- | 0.3372 | -- | 0.5641 | -0.0386 | -0.0386 | 0.1241 | 0.2076 | 0.4725 | -- | 3.54 | 67,415.73 | -14.69 | 4.35 | -16.58 | 5.33 | 46.90 | 62.09 | -31.10 | 6.61 | -- | -- | 0.0312 | 0.00 | -22.89 | 4.32 | -214.15 | -- | 92.12 | -- |
TheraCryf PLC | 396.00k | -3.14m | 3.54m | 9.00 | -- | 0.9687 | -- | 8.95 | -0.0114 | -0.0114 | 0.0014 | 0.0085 | 0.0858 | -- | 0.9766 | 44,000.00 | -67.93 | -42.50 | -81.69 | -46.66 | -- | -- | -792.17 | -1,482.46 | -- | -- | 0.00 | -- | -10.41 | -- | 22.41 | -- | -- | -- |
Destiny Pharma PLC | 0.00 | -5.66m | 4.07m | 19.00 | -- | 0.4406 | -- | -- | -0.0624 | -0.0624 | 0.00 | 0.0965 | 0.00 | -- | -- | 0.00 | -60.33 | -54.32 | -67.28 | -59.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 13.02 | -- | 35.39 | -- |
ImmuPharma PLC | 0.00 | -2.92m | 7.71m | 5.00 | -- | 7.30 | -- | -- | -0.0081 | -0.0081 | 0.00 | 0.0025 | 0.00 | -- | -- | 0.00 | -87.27 | -86.13 | -163.24 | -106.39 | -- | -- | -- | -8,634.98 | -- | -8.61 | 0.00 | -- | -- | -- | 23.26 | -- | -- | -- |
Genflow Biosciences PLC | 0.00 | -1.63m | 7.87m | 5.00 | -- | 9.07 | -- | -- | -0.0056 | -0.0056 | 0.00 | 0.0025 | 0.00 | -- | -- | 0.00 | -88.30 | -- | -105.34 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -21.97 | -- | -- | -- |
Cizzle Biotechnology Holdings PLC | 0.00 | -1.72m | 8.32m | 67.00 | -- | 5.07 | -- | -- | -0.0048 | -0.0048 | 0.00 | 0.0041 | 0.00 | -- | -- | -- | -76.69 | -144.15 | -82.81 | -167.75 | -- | -- | -- | -- | -- | -0.805 | 0.00 | -- | -- | -- | -88.27 | -- | -- | -- |
Synairgen plc | 0.00 | -8.41m | 9.57m | 36.00 | -- | 0.7557 | -- | -- | -0.0418 | -0.0418 | 0.00 | 0.0629 | 0.00 | -- | -- | 0.00 | -44.55 | -54.01 | -51.06 | -60.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 52.35 | -- | -26.64 | -- |
Bivictrix Therapeutics PLC | 0.00 | -2.55m | 10.73m | 12.00 | -- | 3.03 | -- | -- | -0.0351 | -0.0351 | 0.00 | 0.0429 | 0.00 | -- | -- | 0.00 | -57.64 | -- | -65.12 | -- | -- | -- | -- | -- | -- | -- | 0.069 | -- | -- | -- | -1.92 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Rathbones Investment Management Ltd.as of 05 Apr 2024 | 25.79m | 6.04% |
Octopus Investments Ltd.as of 05 Apr 2024 | 21.88m | 5.12% |
Vulpes Investment Management Pte Ltd.as of 11 Apr 2024 | 20.55m | 4.81% |
Hargreaves Lansdown Asset Management Ltd.as of 01 Jun 2024 | 19.16m | 4.48% |
AXA Investment Managers UK Ltd.as of 27 Dec 2023 | 13.40m | 3.14% |
Chelverton Asset Management Ltd.as of 07 Jun 2023 | 12.50m | 2.93% |
RAB Capital Ltd. (Investment Management)as of 07 Jun 2023 | 8.75m | 2.05% |
KW Investment Management Ltd.as of 01 Jun 2024 | 5.60m | 1.31% |
HSBC Bank Plc (Market-Maker)as of 01 Jun 2024 | 5.27m | 1.23% |
IG Markets Ltd.as of 01 Jun 2024 | 4.17m | 0.98% |